FDA officials clarify how diversity action plans intersect with multiregional clinical trials
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsDiversityGlobalGuidanceMedical DevicesPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)